Mini Review•International Open Medical Journal. 1(1):e202501

New Tyrosine Kinase Inhibitors for Lung Cancer

Authors

Kevin Chan1, Mei Wong1, Alan Lee1, Rachel Ho1

Affiliations

1 Department of Medicine, The University of Hong Kong, Hong Kong, China

The treatment of non-small cell lung cancer (NSCLC) has seen significant advancements with the introduction of new tyrosine kinase inhibitors (TKIs) targeting various mutations. The year 2025 has marked an exciting period for the development of novel TKI therapies, with several promising agents coming to the forefront. These new drugs have the potential to revolutionize the treatment landscape for lung cancer, particularly for patients with specific genetic mutations such as HER2 and EGFR.

A recent review by Bouchard and Daaboul (2025) highlighted the emergence of zongertinib, an oral TKI targeting ERRB2 mutations, as a promising therapeutic option for NSCLC patients with HER2 mutations. This drug shows significant promise in clinical trials, offering a more targeted approach compared to traditional therapies, and is poised to become a key player in the personalized treatment of lung cancer (Bouchard & Daaboul, 2025). Furthermore, Liu et al. (2025) identified irreversible HER2 TKIs as a growing class of drugs, particularly effective in first-line treatment regimens for HER2-positive NSCLC. These therapies are expected to improve outcomes by overcoming resistance seen with earlier-generation drugs (Liu et al., 2025).

Additionally, Sun et al. (2025) examined the clinical utility of emerging small molecule compounds, focusing on the development of multi-target TKIs. These new drugs aim to tackle the heterogeneity of NSCLC by targeting multiple mutations simultaneously, which may lead to more durable responses and improved survival rates for patients with complex genetic profiles (Sun et al., 2025). The ongoing clinical trials and research into these novel agents suggest that they could potentially replace or supplement current standard treatments, offering patients a broader range of options.

In conclusion, the landscape of TKI treatment for lung cancer in 2025 is evolving rapidly, with new drugs showing great promise in targeting specific mutations and offering personalized therapeutic approaches. However, continued clinical trials and further studies are needed to fully establish their efficacy and long-term benefits.

References:

1. Bouchard, N., & Daaboul, N. (2025). Lung cancer: targeted therapy in 2025. Current Oncology, 32(3), 146. Link
2. Liu, C., Li, T., Cui, X., Lv, Y., Liu, M., Zhou, X., Yang, F. (2025). Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China. Cancer Research, 45(7). Link

• Sun, M., Yin, Y., Chen, D., Jia, Z. (2025). Small molecules in lung cancer targeted therapy: a two-decade bibliometric analysis and visualization (2005–2024). Clinical Cancer Bulletin, 22(2), 77. Link                                                                                                        
• Publication Dates
•  Publication in this collection
• • 07 July 2025
  •  Date of issue
    2025
  • History
  • Received 22 Oct 2024
  •  Accepted 27 Feb 2025

 This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.